"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02348593 |
Recruitment Status :
Completed
First Posted : January 28, 2015
Results First Posted : July 23, 2019
Last Update Posted : July 23, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Narcolepsy | Drug: JZP-110 Drug: Placebo oral tablet | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 239 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy |
Actual Study Start Date : | May 2015 |
Actual Primary Completion Date : | February 2017 |
Actual Study Completion Date : | February 2017 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 75 mg of JZP-110
Once Daily Dosing
|
Drug: JZP-110 |
Active Comparator: 150 mg JZP-110
Once Daily Dosing
|
Drug: JZP-110 |
Active Comparator: 300 mg of JZP-110
Once Daily Dosing
|
Drug: JZP-110 |
Placebo Comparator: Placebo
Once Daily Dosing
|
Drug: Placebo oral tablet |
- Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 [ Time Frame: Baseline to Week 12 ]Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake; a positive change from baseline represents improvement in the sleep latency time. Mean sleep latency defined as the average of the first 4 MWT trials, if 3 or 4 of them are non-missing.
- Change in ESS Score From Baseline to Week 12 [ Time Frame: Baseline to Week 12 ]
Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness.
The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.
- Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12 [ Time Frame: Baseline to Week 12 ]Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse
- Change in Sleep Latency Time on MWT Trial 1 at Week 12 [ Time Frame: Change from baseline for sleep latency in MWT during trial 1 at week 12 ]Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
- Change in Sleep Latency Time on MWT Trial 2 at Week 12 [ Time Frame: Change from baseline for sleep latency in MWT during trial 2 at week 12 ]Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
- Change in Sleep Latency Time on MWT Trial 3 at Week 12 [ Time Frame: Change from baseline for sleep latency in MWT during trial 3 at week 12 ]Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
- Change in Sleep Latency Time on MWT Trial 4 at Week 12 [ Time Frame: Change from baseline for sleep latency in MWT during trial 4 at week 12 ]Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
- Change in Sleep Latency Time on MWT Trial 5 at Week 12 [ Time Frame: Change from baseline for sleep latency in MWT during trial 5 at week 12 ]Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
- Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-Minute MWT From Baseline to Week 4 [ Time Frame: Baseline to Week 4 ]Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from Baseline to Week 4.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Major Inclusion Criteria:
- Males and females between 18 and 75 years of age, inclusive
- Diagnosis of narcolepsy according to ICSD-3 or DSM-5 criteria
- Body mass index from 18 to <45 kg/m2
- Consent to use a medically acceptable method of contraception
- Willing and able to provide written informed consent
Major Exclusion Criteria:
- Female subjects who are pregnant, nursing, or lactating
- Moderate or severe sleep apnea on the baseline PSG.
- Any other clinically relevant medical, behavioral, or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness
- History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria
- History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy, safety, PK assessments, or the ability of the subject to complete the trial per the judgment of the Investigator
- History of bariatric surgery within the past year or a history of any gastic bypass procedure
- Presence or history of significant cardiovascular disease
- Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness
- Use of any medications that could affect the evaluation of cataplexy
- Received an investigational drug in the past 30 days or five half-lives (whichever is longer)
- Previous exposure to or participation in a previous clinical trial of JZP-110 (ADX-N05, R228060, YKP10A)
- History of phenylketonuria (PKU) or history of hypersensitivity to phenylalanine-derived products

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02348593

Documents provided by Jazz Pharmaceuticals:
Responsible Party: | Jazz Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT02348593 |
Other Study ID Numbers: |
14-002 |
First Posted: | January 28, 2015 Key Record Dates |
Results First Posted: | July 23, 2019 |
Last Update Posted: | July 23, 2019 |
Last Verified: | July 2019 |
Narcolepsy Sleepiness Disorders of Excessive Somnolence Sleep Disorders, Intrinsic |
Dyssomnias Sleep Wake Disorders Nervous System Diseases Mental Disorders |